Alexandria Venture Investments was among the participants in the neurological disease drug developer's series B round.

Xiamen C&D Emerging Industry Equity Investment was among the investors in a $91.8m round that will support the antibody producer's research and development.

The medical data provider has now secured almost $78m in total, with Novartis and Qualcomm venture DRx Capital returning for its series B round.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Novartis will acquire the CNS disorder drug developer after backing its series B round in late 2018, also providing an exit for Access Industries.

Neurodegenerative disease management platform Octave Bioscience has now raised more than $48m in total, Blue Venture Fund and Echo Health Ventures backing its latest round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Alphabet was among the investors in the latest round for life sciences spinoff Verily, which has now disclosed $2.5bn in funding across three rounds.

Ten University of California startups are hoping to open 2021 with a bang by securing one of two $50,000 prizes at the GCV Digital Forum next month.

Biopharmaceutical company Origenis helped form the neurological and immunological disease drug developer, which has revealed series A and B funding.